Breuer, J. and Joppi, R. and Poggiani, C. and Polkowska, M. and Nachtnebel, A. (2014): Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. DSD: Horizon Scanning in Oncology 44.
Breuer, J. and Nachtnebel, A. (2013): Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy . DSD: Horizon Scanning in Oncology 37.
Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.
Fischer, S. and Kisser, A. (2015): Robot-assisted surgery: A systematic review of effectiveness and safety for elected indications and accumulating costs. HTA-Projektbericht 84.
Fischer, S. and Warmuth, M. (2012): Radiofrequency Ablation for the Treatment of Tumours of the Urogenital Tract (Renal Cell Carcinoma, Prostate Cancer and Uterine Leiomyoma). Decision Support Document 59.
Grössmann, N. (2017): Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC). DSD: Horizon Scanning in Oncology 70.
Pramesberger, C. and Adlbrecht, C. and Guba, B. and Felder-Puig, R. (2008): [New minimally invasive methods in the treatment of stress urinary incontinence. Systematic review]. Decision Support Document 06.
Thomas, S. and Janatzek, S. and Geiger-Gritsch, S. and Preuß, C. (2009): Retroluminal transobturatoric reposition sling for the treatment of stress urinary incontinence in men. Systematic Review.. Decision Support Document 30.
Wild, C. (2006): [Diagnostics of urinary incontinence]. HTA-Newsletter 46: 2-3.
Wild, C. (2001): [Sacral neuromodulation in the treatment of urinary incontinence]. HTA-Newsletter 03: 2-3.
Winkler, R. and Rosian, K. (2016): Supply Mandates. HTA-Projektbericht 88.